Stock comparison
LeMaitre Vascular
Organon &
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
OGN
Organon &
Market cap
$3.53B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | OGN | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 57C | LMAT |
| Benjamin Graham | 89A | 78B | LMAT |
| Philip Fisher | 81C | 38D | LMAT |
| Peter Lynch | 67B | 27F | LMAT |
| Joel Greenblatt | 56D | 21F | LMAT |
| Charlie Munger | 68D | 48D | LMAT |
| Terry Smith | 69D | 46D | LMAT |
Side-by-side metrics
| Metric | LMAT | OGN |
|---|---|---|
| Market cap | $2.23B | $3.53B |
| P/E (TTM) | 37.1x | 14.2x |
| EV/EBIT | 36.6x | 8.5x |
| ROIC (TTM) | 9.43% | 5.16% |
| Gross margin | 72.39% | 53.11% |
| Net margin | 24.35% | 3.99% |
| Revenue CAGR 5y | 12.75% | -0.35% |
| EPS CAGR 5y | 19.04% | -39.38% |
| Debt / Equity | 0.5x | 9.5x |
| Dividend yield | 0.84% | 0.6% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- EPS CAGR 5y19.04%vs -39.38%+148%
- Revenue CAGR 5y12.75%vs -0.35%+103%
- Debt / Equity0.5xvs 9.5x+95%
- Net margin24.35%vs 3.99%+84%
OGN leads on
- EV/EBIT8.5xvs 36.6x+77%
- P/E (TTM)14.2xvs 37.1x+62%
- Market cap$3.53Bvs $2.23B+37%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.